Lectin-induced DNA synthesis by peripheral mononuclear cells from 17 normal donors was inhibited (40-60%) by 1,25-dihydroxyvitamin D3 (1,2510H12D3) at physiological concentrations (10-1o-10-9 M). The lymphocytes acquire specific receptors for 1,25(0Hh)D3 upon activation by the lectins. This process precedes the inhibitory effect of 1,25(0Hh)D3. We studied lymphocytes from six patients from four different kindreds with the syndrome of hereditary end-organ resistance to 1,25(OH)2D (the so-called vitamin D-dependent rickets type II). In five patients (three kindreds) peripheral blood mononuclear cells did not acquire receptors for 1,25(OH)2D3 upon phytohemagglutinin-induced activation. Moreover, in contrast to normal lymphocytes, the mitogenic stimulation of these patients' lymphocytes by phytohemagglutinin and concanavalin A was not inhibited by 1,25(0H)2D3. Activated lymphocytes of the sixth patient from a fourth kindred exhibited normal binding of 13H11,25(OH)2D3 but the hormone failed to inhibit the mitogenic stimulation. A similar pattern of the vitamin D effector system was previously observed in fibroblasts cultured from skin biopsies of the same group of patients. The conclusions from these findings are: (a) the inhibition of mitogenic stimulation by 1,25(OH)2D3 is mediated by specific functional receptors to the hormone; and (b) the receptors for 1,25(0H)2D3 in mononuclear cells are probably controlled genetically by the same mechanisms as the effector system in well-characterized target organs of the hormone, such as intestine and kidney.
of vitamin D, the intestine, bone, and kidney, but also in other organs including cellular components of the immune system (3, 4) .
Normal human resting T and B lymphocytes do not contain receptors for 1,25(OH)2D3. However, they acquire such receptors upon lectin-induced stimulation or transformation with EpsteinBarr virus (5, 6) . The receptors can be detected 24 h after lectin treatment (6) .
[3H]Thymidine incorporation into DNA of stimulated peripheral blood T lymphocytes is inhibited by 1,25(OH)2D3 at physiological concentrations (7) . We have demonstrated the presence of high affinity receptors for 1,25(OH)2D3 in medullary mouse thymocytes and their absence from cortical thymocytes. Concomitantly, we have found that 1,25(OH)2D3 inhibits the mitogenic stimulation ofthe medullary cells but has no effect on the stimulation of the cortical cell subpopulation (8) . These data suggest that the inhibitory effect of 1,25(OH)2D3 on lymphocyte response is mediated by specific receptors.
Study of lymphocytes from patients with the syndrome of end-organ resistance to 1, 25 (9) . Using fibroblasts cultured from skin biopsies of these patients, a spectrum of defects in the intracellular receptor mechanism has been demonstrated (10, 1 1 Lymphocyte culture. Human peripheral blood mononuclear cells were obtained from 20-ml blood samples by Ficoll-Hypaque density gradient centrifugation as previously described (13) . Mononuclear cells (I X 1O6/ ml) were suspended in RPMI 1640 medium containing 5% heat-inactivated human AB serum supplemented with penicillin (100 U/ml) and streptomycin (100 Asg/ml). Cells were incubated at 370C in a humidified 5% C02-95% air atmosphere in 0.2-ml aliquots in flat-bottomed Cooke microtiter plates (Nunc, Roskilde, Denmark). Con A (10 ,tg/ml), PHA
(1 ug/ml), and 1,25(OH)2D3 (10-I-10-6 M) were added at zero time.
Cultures were incubated for 68 h.
[3H]Thymidine (1 ,Ci/well) was added 4 h before harvesting. All cultures were carried out in triplicates.
Binding studies. Binding of [3H] 1,25(OH)2D3 to receptors in mononuclear cells was assayed as previously described (8, 10) . Peripheral blood mononuclear cells (I X 106/ml) were incubated with PHA (1 jg/ml) under the same culture conditions described above in 9-cm tissue culture dishes (Nunc), 15 ml/dish. Stimulated cells were harvested after 3 d and washed 3 times with ice cold phosphate-buffered saline. All further procedures were performed at 0-4°C. Cells were suspended in a high KCl buffer (10 mM Tris-HCl, pH 7.4; 300 mM KCl; 10 mM sodium molybdate; 1.5 mM EDTA; 1.0 mM dithiothreitol; and 500 kallikrein inactivator U/ml approtinin). The suspension was sonicated (three 5-s pulses) with Heat-System-Ultrasonics Cell Disruptor model M-375 (Ultrasonic Corp. of America, Hicksville, NY) set at gain 3. The sonicate was centrifuged at 100,000 g for 60 min. The supernatant was saved and will be referred to as "cytosol." Freshly prepared cytosols were incubated with 1 nM [3H]J1,25(OH)2D3 for 17 h at 0°C. Bound [3H]1,25(OH)2D3 was separated from free hormone by the hydroxylapatite batch separation procedure.
Nonspecific binding was assessed under conditions where 1,000-fold excess of cold hormone was present in the binding assay. Protein was determined by the method of Lowry et al. (14) . Protein concentrations in the cytosols were between 1.2 and 2 mg/ml. All binding assays were performed in duplicates.
Statistical analysis. Data of [3Hjthymidine incorporation are presented as mean±SD. Statistical analysis was carried out by means of unpaired t test.
Results
The effect of 1,25(OH)2D3 at different concentrations on Con A-mediated stimulation of mononuclear cells from two normal volunteers is depicted in Table I (6) , and thus receptor appearance precedes the expression of inhibition. The effect of 1,25(OH)2D3 on Con A-induced stimulation of mononuclear cells from children with DDII is depicted in Fig. 1 and Table I . Four separate experiments were carried out, each was performed on cells from children of different kindred, with normal donors serving as controls. The [3H]thymidine incorporation into Con A-stimulated lymphocytes from the six patients was essentially refractory to inhibition by 1,25(OH)2D3. The deviations from control values never reached statistical significance. In contrast, 1,25(OH)2D3 inhibited the mitogenic response of lymphocytes from six normal subjects that served as controls in the same experiments. The inhibition was dose-dependent and ranged between 43 and 52%. The differences between the hormone effect on lymphocytes from patients and respective normal donors were highly significant (P < 0.001) ( Fig. 1 and Table I) .
We have studied the binding of 1,25(OH)2D3 to mononuclear cells stimulated by PHA. The cell preparations used in the binding experiments were the same as in the stimulation-inhibition experiments shown in Fig. 1 and Table I. In the binding experiments we used PHA-rather than Con A-stimulated cells, since PHA was more effective in generation of receptors for 1,25(OH)2D3, probably due to its higher potency as a mitogen. As shown in Table II pooled and compared with the control. The inhibition of thymidine incorporation for all normal donors was statistically significant (P < 0.001). The values for DDII patients were not significantly lower than the control values (P > 0.05). The differences between patients and respective controls were statistically significant (P < 0.001) for all kindreds.
described above. On the other hand, lymphocytes from patients with DDII are resistant to the inhibitory effect of the hormone. Occasionally, we observed an enhancing effect of 1,25(OH)2D3 on PHA-induced thymidine incorporation into lymphocytes from these patients. However, this effect was not dose-dependent (data not shown) and was statistically significant only in two out of the six patients. The binding of [3H] 1 ,25(OH)2D3 to cytosols of PHA-stimulated mononuclear cells from patients with DDII is practically undetectable in patients la, 2, 3a, and 3b, and normal in patient 4. The lack of binding of 1,25(OH)2D3 to lymphocytes from some of the patients could not be attributed to a reduction in the mitogenic response, since the rate of thymidine incorporation for cell preparations from patients is similar to the rate for normal donors (Table II) . It should be noted that although the extent of inhibition by 1,25(OH)2D3 is remarkably similar among different individuals (41-47%), the Fig. 1 
Discussion
Recent studies suggest that the inhibition of lymphocyte proliferation by 1,25(OH)2D3 is mediated by a specific high-affinity receptor. This assumption is based mainly on indirect evidence: the inhibitory dose of 1,25(OH)2D3 which causes half maximal effect is similar to the dissociation constant observed in parallel binding studies (-2 X 10-10 M); the relative efficacy of vitamin D metabolites as inhibitors is similar to their known affinity for the receptor binding site (7) and, finally, a subpopulation of mouse thymocytes that does not have a high affinity receptor is insensitive to inhibition (8) .
Skin fibroblasts obtained from the patients included in this study with clinical evidence of end-organ resistance to 1,25(OH)2D showed a receptor pattern similar to the one observed by us in their stimulated mononuclear cells (Table II) : normal for patient 4 and undetectable for the others. Neither of these patients responded clinically or biochemically to prolonged treatment with high doses of vitamin D or its la-hydroxylated metabolites. The induction of 25-hydroxyvitamin D 24-hydroxylase by 1,25(0H)2D3 in cultured skin fibroblasts may serve as a biochemical marker for the effect of the hormone in vitro. No induction of the enzyme was observed in cultured skin fibroblasts from all four kindreds (reference 11 and unpublished observation). We show here that 1,25(OH)2D3 fails to inhibit the proliferation of mitogen-stimulated lymphocytes from the same patients that have defective effector systems for the hormone, including the patient with normal binding.
This finding strongly supports the conclusion that the receptor for 1,25(OH)2D3 mediates the inhibitory effect ofthe hormone on lymphocyte stimulation and that this effect requires the presence of an intact coupling between receptor binding and subsequent events. The expression of this receptor in mononuclear cells is probably genetically controlled by the same mechanism as the expression of receptors in skin fibroblasts and classical target organs like intestine and kidney. The susceptibility of mononuclear cells to inhibition by 1,25(OH)2D3 can readily be used to diagnose patients with total or partial end-organ resistance to 1,25(OH)2D. Peripheral blood mononuclear cells provide an easily accessible and useful cellular source which may serve as a model for the study of the mechanism of 1,25(OH)2D3 action under physiological and pathological conditions.
